Screen Failure

Screen Failure

  1. lut 28, 2025

What Does the 'Screen Failure’ Mean?

Screen failure refers to a situation in clinical trials where a potential participant does not meet all the eligibility criteria during the screening process. This occurs when an individual fails to satisfy one or more of the inclusion criteria or meets any of the exclusion criteria specified in the study protocol.

Screen failures are an important aspect of clinical research as they help ensure that only suitable participants are enrolled in a study. They contribute to maintaining the integrity and validity of clinical trial data by excluding individuals who may introduce confounding factors or increased risks.

Why Is the 'Screen Failure’ Important in Clinical Research?

Screen failures play a crucial role in maintaining the scientific rigor and safety of clinical trials. By identifying participants who do not meet the study criteria, researchers can ensure that the collected data accurately represents the intended population and minimizes potential confounding factors.

Understanding screen failure rates is essential for trial planning and resource allocation. It helps researchers and sponsors estimate the number of potential participants needed for screening to achieve the desired enrollment, ultimately impacting study timelines and budgets.

Good Practices and Procedures

  1. Implement a tiered screening process, starting with non-invasive assessments before progressing to more complex or invasive procedures, to minimize participant burden and resource utilization.
  2. Conduct thorough training for site staff on protocol-specific inclusion/exclusion criteria to ensure consistent application across all potential participants.
  3. Utilize electronic data capture systems with built-in eligibility checks to reduce human error and streamline the screening process.
  4. Perform regular interim analyses of screen failure rates to identify trends and adjust recruitment strategies or protocol amendments if necessary.
  5. Maintain detailed documentation of reasons for screen failures to inform future protocol designs and improve participant selection criteria.

Related Terms

Resources

Axcellant Establishes Advisory Board to Strengthen Clinical and Strategic Leadership

Axcellant is pleased to announce the formation of its Advisory Board - a group of distinguished experts in clinical science,…

One trial is no longer enough. Regulators on both sides of the Atlantic are building a new model of clinical evidence

The FDA and the European Commission are changing the rules of the game simultaneously. The shift is from a single…

Imaging Core Lab in Nuclear Medicine: Standardization, Quality Control, and Regulatory Alignment in Clinical Trials 

Modern nuclear medicine is a high-tech discipline that requires advanced facilities, infrastructure, qualified staff, and know-how. The reliable supply of radionuclides,…